x
Ariana Pharma
[contact-form-7 404 "Not Found"]

Ariana Pharma
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News & more
    • In The News
    • Case study
    • Publications
      • Publications & Conferences
      • Whitepaper & blog
  • Careers
Logo

Contact Info

  • 58-60 Avenue de la Grande Armée, 75017, Paris, France
  • +33 1 44 37 17 00
  • info@arianapharma.com

Advancing Clinical Trials: The Role of Synthetic Control Arm

Overview

Ariana successfully created a Synthetic Control Arm (SCA) to evaluate the efficacy of a treatment against Alzheimer. Leveraging its Real World Data (RWD) capabilities, Ariana applied matching strategy to identify untreated patient from a public database having the same clinical characteristics and inclusion criteria of treated patients from an Alzheimer clinical study. SCAs offer a desirable alternative to traditional randomized controlled trials (RCTs) by allowing for the comparison of treated patients against a cohort of untreated patients digitally created.

Impact

• SCAs address ethical concerns associated with withholding potential treatments from control groups in life-threatening conditions or when no standard treatment exists. They also mitigate challenges in recruiting sufficient patients for rare or progressive diseases.

• Within the KEM® platform, the SCA module designed by Ariana provides a sound basis for assessing treatment efficacy, potentially accelerating drug development and approval processes.

Objectives

• Leverage comprehensive RWD to construct SCAs that accurately reflect the characteristics of traditional trial control arms without the enrollment of actual patients into placebo groups.

• Provide an assessment of treatment efficacy.

Method

Matched controls were selected from extensive external databases using propensity score combined with advanced matching algorithms (e.g., nearest neighbor matching, genetic matching) that consider multiple baseline characteristics such as age, sex, and disease severity. These synthetic arms are then used to mimic control groups in clinical trials, providing a comparator for treated patients.

Used Case

The SCA module of Ariana combined with Real World Data (RWD) capabilities were used to assess the efficacy of a phase IIa Alzheimer treatment. The synthetic control arm was constructed from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database.It demonstrated significant efficacy in mirroring the natural progression of untreated Alzheimer’s disease, thereby validating the therapeutic effects of the drug treatment.

 

Ariana Pharmaceuticals, The AI DRUG Development Company

  • Paris, FRANCE / Cambridge, MA, USA
  • Call Us: +33 144 37 17 00
  • info@arianapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Ariana Pharma © 2024 All Rights Reserved